TOP
|
Aibeta Combination Ophthalmic Solution(¾ÆÊ¯ËáäåĪÄᶨ/ÂíÀ´ËáÌæÄªÂå¶û¸´ºÏµÎÑÛÒº)
|
|
|
 |
Ò©µê¹ú±ð£º |
|
²úµØ¹ú¼Ò£º | ÈÕ±¾ |
´¦ ·½ Ò©£º | ÊÇ |
ËùÊôÀà±ð£º | 1ºÁ¿Ë/5ºÁÉý+6.8ºÁ¿Ë/5ºÁÉýÆ¿ 10Æ¿/ºÐ |
°ü×°¹æ¸ñ£º |
1ºÁ¿Ë/5ºÁÉý+6.8ºÁ¿Ë/5ºÁÉýÆ¿ 10Æ¿/ºÐ |
¼Æ¼Ûµ¥Î»£º |
ºÐ |
Éú²ú³§¼ÒÖÐÎIJο¼ÒëÃû: |
ǧÊÙÖÆÒ© |
Éú²ú³§¼ÒÓ¢ÎÄÃû: |
Senju Pharmaceutical Co.Ltd. |
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·1: |
|
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·2: |
|
¸ÃÒ©Æ·Ïà¹ØÐÅÏ¢ÍøÖ·3: |
|
|
Ô²úµØÓ¢ÎÄÉÌÆ·Ãû: |
Aibeta Combination Ophthalmic Solution£¨¥¢¥¤¥Ù©`¥¿ÅäºÏµãÑÛÒº£©10Vial¡Á5ml |
Ô²úµØÓ¢ÎÄÒ©Æ·Ãû: |
Brimonidine Tartrate/Timolol Maleate |
ÖÐÎIJο¼ÉÌÆ·ÒëÃû: |
Aibeta¸´ºÏµÎÑÛÒº£¨¥¢¥¤¥Ù©`¥¿ÅäºÏµãÑÛÒº£©10Æ¿¡Á5ºÁÉý |
ÖÐÎIJο¼Ò©Æ·ÒëÃû: |
¾ÆÊ¯ËáäåĪÄᶨ/ÂíÀ´ËáÌæÄªÂå¶û |
ÔøÓÃÃû: |
|
|
|
¼ò½é£º
²¿·ÝÖÐÎľÆÊ¯ËáäåĪÄᶨ/ÂíÀ´ËáÌæÄªÂå¶û´¦·½×ÊÁÏ£¨½ö¹©²Î¿¼£©
Ó¢ÎÄÃû£ºBrimonidine Tartrate/Timolol Maleate
É̱êÃû£ºAIBETA
ÖÐÎÄÃû£º¾ÆÊ¯ËáäåĪÄᶨ/ÂíÀ´ËáÌæÄªÂå¶û¸´ºÏµÎÑÛÒº
Éú²úÉÌ£ºÇ§ÊÙÖÆÒ©
¥¢¥¤¥Ù©`¥¿ÅäºÏµãÑÛÒº
Ò©Ó÷ÖÀàÃû³Æ
α2¼¤¶¯¼Á/β×èÖͼÁ»ìºÏ¼Á.Çà¹âÑÛ/¸ßÑÛѹÖÎÁƼÁ
Åú×¼ÈÕÆÚ£º2019Äê9ÔÂ
É̘ËÃû
AIBETA COMBINATION OPHTHALMIC SOLUTION
¥Ö¥ê¥â¥Ë¥¸¥ó¾ÆÊ¯Ëá‰c
Ò»°ãµÄÃû³Æ
¥Ö¥ê¥â¥Ë¥¸¥ó¾ÆÊ¯Ëá‰c
£¨Brimonidine Tartrate£©¡²JAN¡³
»¯Ñ§Ãû
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl) quinoxalin-6-amine mono-(2R,3R)-tartrate
·Ö×Óʽ
C11H10BrN5・C4H6O6
·Ö×ÓÁ¿
442.22
ÐÔ×´
¾ÆÊ¯ËáäåĪÄᶨÊǰ×É«ÖÁµ»ÆÉ«·ÛÄ©¡£
ÈÝÒ×ÈÜÓÚË®£¬²»Ò×ÈÜÓÚ¶þ¼×»ù¼×õ£°·»ò¼×´¼£¬±ûͪ£¬¼¸ºõ²»ÈÜÓÚ¶þÂȼ×Íé»òÒÒËáÒÒõ¥¡£
»¯Ñ§˜‹Ôìʽ
¥Á¥â¥í©`¥ë¥Þ¥ì¥¤¥óËá‰c
Ò»°ãµÄÃû³Æ
¥Á¥â¥í©`¥ë¥Þ¥ì¥¤¥óËá‰c
£¨Timolol Maleate£©¡²JAN¡³
»¯Ñ§Ãû
(2S)-1-[(1,1-Dimethylethyl)amino]-3-(4-morpholin-4-yl-1,2,5-thiadiazol-3-yloxy)propan-2-ol monomaleate
·Ö×Óʽ
C13H24N4O3S・C4H4O4
·Ö×ÓÁ¿
432.49
ÐÔ×´
Áò´¼ÐÛÐÔËáÑÎÊǰ×É«ÖÁµ»ÆÉ«°×É«½á¾§·ÛÄ©¡£
ÈÝÒ×ÈÜÓÚ´×Ëᣨ100£©£¬Ò×ÈÜÓÚË®»òÒÒ´¼£¨99.5£©¡£
ÈܽâÔÚ0.1mol/LÑÎËáÊÔÒºÖС£
»¯Ñ§½á¹¹¹«Ê½
ÈÛµã
Ô¼197°C£¨·Ö½â£©
Åú×¼Ìõ¼þ
ÖÆ¶¨²¢Êʵ±ÊµÊ©Ò©Æ··çÏÕ¹ÜÀí¼Æ»®¡£
ҩЧҩÀí
×÷ÓûúÖÆ
²¼ÀïĪÄá¶¡¾ÆÊ¯ËáÑÎ
²¼ÀïĪÄá¶¡×÷ÓÃÓÚÉöÉÏÏÙËØ+2-ÊÜÌ壬±»ÈÏΪͨ¹ýÒÖÖÆÄ¤Ç¿Ä¤Á÷³ö·¾¶ÒÖ֯Ĥ²úÉúºÍ´Ù½øÁ÷Ë®Á÷³öÀ´½µµÍÑÛѹ¡£
ÔÚµ¥Ä¿Íõ¥ÑÛÖжÔ0.3%²¼ÀïĪÄá¶¡¾ÆÊ¯ËáÑÎÈÜÒº½øÐе¥Ä¿ÑÛÒ©Ë®ÊÔÑ飨·ú¹â¶È²â¶¨·¨£©£¬¹Û²ìµ½ÓëÑÛÑÛ1СʱºóÏà±È£¬ÒÖÖÆ³ö¸ß´ï43.9%µÄ·ÖË®Éú²ú¡£
ÔÚ¸ßÑÛѹ»¼Õߵĵ¥ÑÛÑÛÖУ¬¶Ô0.2%²¼ÀïĪÄá¶¡¾ÆÊ¯ËáÑÎÑÛÒº½øÐÐÑÛÒ©Ë®ÊÔÑ飨·ú¹â¶È²â¶¨·¨£©£¬ÒÖ֯Ĥ²úÉú£¬´Ù½øÆÏÌÑĤǿĤÁ÷³öͨµÀµÄÅÅË®£¨Íâ¹úÊý¾Ý£©¡£
Áò´¼ÐÛÐÔËáÑÎ
Áò´¼¶ÔÉöÉÏÏÙËØβ-ÊÜÌåÎÞÑ¡ÔñÐÔµØ×÷Ó㬱»ÈÏΪͨ¹ýÒÖÖÆË®Éú³ÉÀ´½µµÍÑÛѹ¡£
ºï×Ó£¬ÔÚ½¡¿µÊÜÊÔÕߵķú¹â¶È²âÊÔºÍÇà¹âÑÛ»¼ÕߵĵØÐβâÊÔÖУ¬Áò´¼Ã÷ÏÔÒÖÖÆË®Éú³É¡£
ÑÛѹϽµ×÷ÓÃ
²¼ÀïĪÄá¶¡¾ÆÊ¯ËáÑÎ
ÓÉÓÚµ¥´ÎÑÛÒ©Ë®¶ÔÍÃ×ÓÊ©ÓÃ0.000015%ÖÁ0.15%²¼ÀïĪÄᶡʯËáÑÎÈÜÒº£¬¹Û²ìµ½Å¨¶ÈÒÀÀµÐÔÑÛѹ½µ×÷Óá£
Áò´¼ÐÛÐÔËáÑÎ
ÔÚÍÃÖÐα-¼¡ëÄÒýÆðµÄ¸ßÑÛѹºÍË®¸ººÉÒýÆðµÄÑÛѹÔö¼ÓÊÔÑéÖУ¬¹Û²ìµ½Áò´¼ÐÛÐÔËáÑεÄÑÛÒ©Ë®ÏÔÖøÒÖÖÆÑÛѹÔö¼Ó¡£
ÊÊÓ¦Ö¢
Èç¹ûÆäËûÇà¹âÑÛÖÎÁÆÒ©ÎïÔÚÒÔϼ²²¡ÖÐЧ¹û²»×㣺Çà¹âÑÛ¡¢¸ßÑÛѹ
Ó÷¨ÓëÓÃÁ¿
Ò»´ÎµÎ£¬Ã¿ÌìÁ½´Î¡£
°ü×°
ËÜÁÏÑÛÑÛÈÝÆ÷
1ºÁ¿Ë/6.8ºÁ¿Ë
5mLx5£¬5mLx10
ÖÆÔ칩ӦÉÌ
ǧÊÙÖÆÒ©ÓÐÏÞ¹«Ë¾
ÏúÊÛ
ÎäÌïÖÆÒ©ÓÐÏÞ¹«Ë¾
ÌáЯ
´ó‰VÑuËaÖêʽ»áÉç
´¢ÐîºÍÓÐЧÆÚ
´¢Ðî·½·¨
ÊÒδ¢´æ
ÓÐЧÆÚ
Á½ÄêÁË
Àà±ð
´¦·½Ò©£¨Ò½ÉúµÈ£©×¢£©
×¢Ò⣺ ¿Éͨ¹ýÒ½ÉúµÄ´¦·½Ê¹ÓÃ
×¢£ºÒÔÉÏÖÐÎÄ×ÊÁϲ»¹»ÍêÕû£¬Ê¹ÓÃÕßÒÔÔ´¦·½×ÊÁÏΪ׼¡£
ÍêÕû˵Ã÷Ê鸽¼þ£º
http://www.info.pmda.go.jp/go/pack/13198A5Q1021_1_02/?view=frame&style=XML&lang=ja |
|
|
¡¾´ó ÖРС¡¿¡¾´òÓ¡¡¿
¡¾·±Ìå¡¿¡¾Í¶¸å¡¿¡¾Êղء¿
¡¾ÍƼö¡¿¡¾¾Ù±¨¡¿¡¾ÆÀÂÛ¡¿
¡¾¹Ø±Õ¡¿ ¡¾·µ»Ø¶¥²¿¡¿ |
|
ÉÏһƪ£ºBrinzolamide Ophthalmic suspens.. |
ÏÂһƪ£ºAibeta Combination Ophthalmic S.. |
|